- March 08, 2023Source: YaleNews
Bosenberg Named Brady Professor of Dermatology, Pathology, and Immunobiology
- February 01, 2023
Study Finds Large Gap in Breast Cancer Treatment Recommendations for Patients Aged 70 vs 69
- February 01, 2023
Trial Shows Significant Disease-free Survival for Patients Diagnosed With Non-small Cell Lung Cancer
- January 26, 2023
Older Patients Left Behind in Progress Against Lung Cancer, Yale Study Shows
- January 26, 2023
Yale Scientists Enable Massively Parallel DNA Insertions Into Human Cells
- December 16, 2022Source: Yale SEAS
With Discovery, Oxygen's Role in Growth of Tumors Reconsidered
- October 21, 2022
Oncology Therapy at the End of Life: Have We Missed the Mark?
- July 28, 2022
A New Path for Treating Brain Cancer With a Yale-developed Compound
- June 28, 2022
Defining the Landscape of Prostate Cancer Treatment
- May 16, 2022
PROTAC Research Takes Aim at Drug Resistant Prostate Cancer
- May 16, 2022
Pancreatic Cancer: Team Science Propels New Ideas
- May 16, 2022
BRCA Experts Rally to Research DNA Repair for Better Breast, Ovarian and Other Cancer Treatments
- May 16, 2022
A Faster, Broader Pipeline for Phase I Clinical Trials Investigating Immunotherapies, Targeted Therapies
- May 11, 2022
Viruses and Cancer: How a 45-year Legacy of Collaboration Led to Discoveries about Epstein-Barr, SV40
- September 20, 2020
Head and Neck Cancer Research Leaps Forward With Yale’s NIH SPORE Award
- March 19, 2020
Lung Cancer: Research Leads to New Immunotherapy Drug Approval,Insights on EGFR Resistance
Cancer
Yale Cancer Center embraces a tradition of innovative cancer treatment and quality care. A National Cancer Institute (NCI) designated comprehensive cancer center for over 45 years, Yale Cancer Center is one of only 51 such centers in the United States. Cancer care is available to patients and families through Smilow Cancer Hospital and the Smilow Cancer Hospital Network through multidisciplinary teams who work together to make sure that every aspect of a patient’s treatment plan is personalized and well managed. Smilow Cancer Hospital is accredited by the Commission on Cancer, a Quality program of the American College of Surgeons, and recognized by the American Society of Clinical Oncology with a Quality Oncology Practice Initiative (QOPI) certification.
A world leader in cancer care, research, and education, Yale Cancer Center delivers the transformative scientific discoveries and care innovations of Smilow Cancer Hospital and Yale School of Medicine to bring us closer to a world free of cancer–one patient at a time. Recent advances in immunotherapy to treat certain cancers have been transformational, and Yale Cancer Center and Smilow Cancer Hospital are leaders in the cancer immunotherapy revolution.
Members of six cancer research programs led 793 scientific publications in 2021, generating new data, new discussions, and new outcomes to meaningfully improve the course of cancer care. The collaborations between Yale Cancer Center’s research programs and Smilow Cancer Hospital’s clinical centers are advancing innovations from laboratories to benefit patients while, at the same time, bringing data back to inform future laboratory discoveries. Over the next five years, this momentum will strengthen, further positioning Yale Cancer Center and Smilow Cancer Hospital as national and international leaders in cancer research and care, while also tackling issues of disparities and inequities in our community.
If we pay attention to our patients, we learn so much about what to pursue in our research and how to provide the care in clinic. We can provide the best care today and learn how to make it ever so much better in the future—that’s what drives me to build an even stronger cancer center and programs at Smilow that focus on patient experience.